top of page
Dr. Liang Liu - Pancreatic Surgeon - Zhongshan Hospital Shanghai

Professional Title & Qualifications:

Chief Physician, Professor, Dual Doctoral Supervisor (Surgery & Oncology)

Specialization: 

Pancreatic Surgery, General Surgery

Hospital & Department：

Shanghai Zhongshan Hospital, Fudan University – Department of Pancreatic Surgery

Dr. Liang Liu - Pancreatic Surgeon

Personal Biography

Dr. Liang Liu is a Chief Physician, Professor, and a dual doctoral supervisor in Surgery and Oncology. He currently serves as the Director of the Department of Pancreatic Surgery at Zhongshan Hospital, Fudan University, having been recruited in 2022. Dr. Liu was the first author for the 2012, 2018, and 2020 editions of the "Clinical Diagnostic Standards for Pancreatic Cancer in China" and "Comprehensive Diagnosis and Treatment Guidelines for Pancreatic Cancer in China."

 

He is an expert member on several national-level committees, including the Pancreatic Cancer Project Group for the Chinese Academy of Sciences and National Natural Science Foundation, the "National Large-scale Science Project" Pancreatic Cancer Group, and the National Cancer Center's Pancreatic Cancer Quality Control Expert Committee. For his work in identifying and providing treatment strategies for "non-beneficial surgery" subgroups in pancreatic cancer, he was awarded the "2010 Asian Young Oncologist Outstanding Contribution Award," being the only scholar from mainland China to receive this honor that year. He is an active member of the American Society of Clinical Oncology (ASCO) and the Japanese Cancer Association (JCA).

Book an online consultation with Dr. Liang Liu

Areas of Expertise

  • Comprehensive surgical diagnosis and treatment for benign and malignant pancreatic tumors, pancreatic neuroendocrine tumors, tumors of the lower biliary tract and duodenum, spleen tumors, and retroperitoneal/unknown primary abdominal tumors.

  • Specializes in large-scale surgeries for "converting unresectable to resectable" cases following conversion therapy.

  • Specializes in extra-large-scale surgeries such as "combined liver-pancreas resection."

  • Performed China's first "sequential pancreaticoduodenectomy after in-situ liver transplantation" (2022).

  • Performed the world's first "simultaneous in-situ liver transplantation combined with total pancreatectomy" (2023).

  • Performed Zhongshan Hospital's first "in-situ liver transplantation sequential subtotal pancreatectomy after five previous abdominal surgeries" (2024).

Clinical Highlights

  • Over 4,000 patients treated

  • 100% treatment satisfaction rate

  • 100% patient satisfaction with service attitude

​

Work Experience

  • Director, Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University (2022-Present)

  • Visiting Scholar (Abdominal Surgery and Organ Transplantation), Freiburg University, Germany (Jan 2005 - Jan 2007)

Social Appointments

  • Member, American Society of Clinical Oncology (ASCO)

  • Member, Japanese Cancer Association (JCA)

  • Expert, "Precision Medicine Development Strategy Research" Project Group, Chinese Academy of Sciences & National Natural Science Foundation of China

  • Expert, "National Large-scale Science Project" Pancreatic Cancer Project Group

  • Committee Member, Pancreatic Cancer Quality Control Expert Committee, National Cancer Center

  • Deputy Group Leader, Clinical Research Working Group, Surgical Branch, Chinese Medical Doctor Association

  • Deputy Group Leader, Neuroendocrine Oncology Group, Oncology Branch, Chinese Medical Doctor Association

  • Committee Member, Pancreatic Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)

  • Committee Member, Neuroendocrine Tumor Expert Committee, Chinese Society of Clinical Oncology (CSCO)

  • Standing Committee Member, Peritoneal Oncology Professional Committee, China Anti-Cancer Association (CACA)

  • Standing Committee Member, Pancreatic Tumor Professional Committee, International Hepato-Pancreato-Biliary Association (IHPBA), China Branch

  • Member, Pancreatic Group, General Surgery Branch, Shanghai Medical Association

Awards and Honors

  • "Asian Young Scientist Award" (2010), Japanese Cancer Association

  • "Tang Zhaoyou-CCB Fund" First Prize (2010, 2011)

  • "Outstanding Medical Talent" (2015), Shanghai "Medical Elite Star" Program

  • Cover Figure (2015), World Chinese Journal of Digestology

  • PCCA-CSPAC-Celgene Fund Outstanding Physician of the Year Award (2016)

  • First Prize, Shanghai Innovation Achievement Award (2019) (As main contributor)

  • First Prize, Shanghai Medical Science and Technology Award (2020) (As main contributor)

  • First Prize, China Anti-Cancer Association Science and Technology Progress Award (2020) (As main contributor)

  • "Shanghai Outstanding Academic Leader" (2023)

  • "Famous Doctor of China" (6th Edition) (2023)

  • "Oriental Talent" (Top-notch Project) (2024)

Research Achievements

  • Published 93 SCI papers as first or corresponding author in international surgery or oncology journals (including 25 papers with IF > 10).

  • Principal Investigator for numerous national-level projects, including: 6 NSFC General Program grants, 1 NSFC Major Research Instrument Development project, 1 NSFC International Cooperation & Exchange project, the National Cancer Center "Climbing" Fund, the National Key R&D Program, and the Ministry of Education's Doctoral Program Special Research Fund.

  • Research findings have been featured in major media outlets such as Wen Wei Po, Jiefang Daily, Guangming Daily, and Reference News.

  • Co-authored (as deputy chief editor) the first academic monograph of the Shanghai Pancreatic Tumor Institute: "Diagnosis and Treatment of Pancreatic Cancer - New Technologies, New Concepts, New Strategies."

*The doctor’s information is sourced from the hospital’s official website or provided directly by the doctor. Due to update cycles, there may be occasional delays in reflecting the most recent changes.

Have questions about our medical concierge services?

bottom of page